AlbionVentures
Portfolio
Xceleron Limited
Xceleron has pioneered the use of AMS analysis in pre-clinical and clinical development. AMS analysis can provide human metabolism data at a far earlier stage in the drug development process than traditional methods, enabling better candidate selection and hence reducing development costs.
Sector
Healthcare
Amount Invested
£4.3m
Location
York
Deal type
Growth Capital
Year invested
2005
www.xceleron.com
